drugset / Trial / NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Timeline
- Start
- 2005-12
- Primary completion
- 2011-02
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | alvocidib | Small molecule | 30 mg/m2 | Intravenous |
| Subject | alvocidib | Small molecule | 50 mg/m2 | Intravenous |
Indications
Hodgkin's lymphoma, lymphocytic depletion
Hodgkin's lymphoma, mixed cellularity
MALT lymphoma
Waldenstrom macroglobulinemia
adult T-cell leukemia/lymphoma
adult nodular lymphocyte predominant Hodgkin lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
grade III lymphomatoid granulomatosis
mantle cell lymphoma
mycosis fungoides and variants
nodal marginal zone B-cell lymphoma
nodular sclerosis classical Hodgkin lymphoma
plasma cell myeloma
splenic marginal zone lymphoma